266 related articles for article (PubMed ID: 16899784)
1. A proposal for radical changes in the drug-approval process.
Wood AJ
N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
[No Abstract] [Full Text] [Related]
2. [FDA's new drug approval system].
Ishii A
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1146-51. PubMed ID: 7661565
[No Abstract] [Full Text] [Related]
3. Drug safety on trial.
Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
[No Abstract] [Full Text] [Related]
4. Drug safety special: the safety catch.
Wadman M
Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
[No Abstract] [Full Text] [Related]
5. Improving how we evaluate the toxicity of approved drugs.
Reidenberg MM
Clin Pharmacol Ther; 2006 Jul; 80(1):1-6. PubMed ID: 16815311
[No Abstract] [Full Text] [Related]
6. Dermatology clinical trials and drug development.
Ehrenberger HE; Joshi TG
Dermatol Nurs; 2003 Oct; 15(5):428-34. PubMed ID: 14619320
[No Abstract] [Full Text] [Related]
7. The FDA's drug review process: ensuring drugs are safe and effective.
Meadows M
FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
[No Abstract] [Full Text] [Related]
8. Drug development process for a product with a primary pediatric indication.
Allen AJ; Michelson D
J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
[TBL] [Abstract][Full Text] [Related]
9. [From molecule to medicine--drug development].
Bruhn C
Dtsch Med Wochenschr; 2010 Feb; 135(6):p5. PubMed ID: 20151355
[No Abstract] [Full Text] [Related]
10. The generic drug approval process.
Rheinstein PH
Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
[No Abstract] [Full Text] [Related]
11. FDA guidance document on monitoring delayed adverse events a good first start.
Williams DA
Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
[No Abstract] [Full Text] [Related]
12. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
Koivuniemi PJ
Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
[No Abstract] [Full Text] [Related]
13. Drug safety. Gaps in the safety net.
Couzin J
Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
[No Abstract] [Full Text] [Related]
14. Safety in numbers--monitoring risk in approved drugs.
Okie S
N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
[No Abstract] [Full Text] [Related]
15. The drug approval process at the Food and Drug Administration. New biotechnology as a paradigm of a science-based activist approach.
Miller HI; Young FE
Arch Intern Med; 1989 Mar; 149(3):655-7. PubMed ID: 2645844
[No Abstract] [Full Text] [Related]
16. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
Shulman SR; Brown JS
Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
[No Abstract] [Full Text] [Related]
17. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
Goldman SA
Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
[No Abstract] [Full Text] [Related]
18. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry.
O'Reilly JT
Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328
[No Abstract] [Full Text] [Related]
19. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
20. Drug development research: the process.
Sataloff RT
Ear Nose Throat J; 2008 Aug; 87(8):420-2. PubMed ID: 18712686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
